🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05807984
Starting soon Phase 2

Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion

NCT05807984 · tracked via the Priya Life Science China tracker
Sponsor
Xin Cai
Phase
Phase 2
Started
2023-05-01
Last updated
2023-04-11

Condition(s) studied

Rectal CancerRecurrent

Investigational drug(s) / intervention(s)

Carbon ion radiation therapy DT: 74Gy/20 fractions

Carbon ion radiation therapy DT: 74Gy/20 fractions: patients with unresectable local recurrent rectal cancer will be treated with carbon ion radiation therapy as re-irradiation

Study summary

Prospective phase II clinical study aim to explore the clinical outcome of patients with unresectable locally recurrent rectal cancer (LRRC) treated with re-irradiation by carbon ion radiotherapy (CIRT)

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * 1\) pathologically confirmed rectal adenocarcinoma (including mucinous adenocarcinoma and signet-ring cell carcinoma) and LRRC confirmed by biopsy or clinical diagnosis, * 2\) received a radical operation for their primary tumor and regional lymph nodes, * 3\) received chemo-radiation or radiation in pelvic before CIRT, * 4\) received re-irradiation by CIRT after their pelvic radiotherapy. Exclusion Criteria: * 1\) received more than once prior radiotherapy in the same treatment field, * 2\) time to the last radiotherapy was \<1 year, * 3\) space between the lesion to organ at risk (OARs) (bladder or digestive tract) was too close (\<5 mm).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Proton and Heavy ion center Shanghai Pudong

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05807984 on ClinicalTrials.gov ↗ ← All trials in China